Tenderwize
Back to tender search

Framework contracts for innovative infectious disease therapeutics

Health and Digital Executive Agency (HaDEA)·Brussels, Belgium·EUR 252M·Deadline Sep 02, 2026 · 12 days left·Neg W Call·Services·Framework
Sign up to saveOpen documents
High value
Original notice title

Belgium – Research and development services and related consultancy services – Multiple sourcing Framework Contracts to speed up the development of and access to innovative medical countermeasures Next Generation Therapeutics for Infectious Diseases

75/100

Opportunity Score

PromisingHigh complexity
ServicesFrameworkOpen
Why this score?

Opportunity

75 / 100

Complexity

85 / 100

Risk factors

Highly innovative and specialized therapeutic areas (e.g., host-targeted, broad-spectrum) may require cutting-edge R&D...

Procurement documents are not analyzed; detailed requirements, terms, and conditions may impose unforeseen obligations.

Submission deadline in 12 days

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Strong opportunity

Key Facts

  • EUR 252M estimated value
  • Framework procurement
  • Services contract
  • 2 lots
  • Lot 1: Development of pathogen-targeted scalable therapeutics, innovative combination therapies, and alternative IV route products for viral infections, ARDS, or sepsis.
  • Lot 2: Development of host-targeted scalable therapeutics, innovative combination therapies, and alternative IV route products for viral infections, ARDS, or sepsis.
Show full summary

This Pre-Commercial Procurement (PCP) call, led by the Health and Digital Executive Agency (HaDEA), aims to accelerate the development of innovative medical countermeasures for infectious diseases, specifically next-generation therapeutics. The tender consists of two lots: 'Highly Innovative Therapeutics' (Lot 1, value €138M) focusing on pathogen-targeted scalable therapeutics, and 'Advanced Therapeutics' (Lot 2, value €114M) focusing on host-targeted scalable therapeutics. Both lots include combination therapies and alternative IV routes. The overall estimated value is €252M, funded under EU4Health. The procedure is a negotiated procedure with call for competition, resulting in multiple sourcing framework contracts. Evaluation is 80% quality and 20% price. Submission deadline: 2026-09-02.

Risks

Highly innovative and specialized therapeutic areas (e.g., host-targeted, broad-spectrum) may require cutting-edge R&D...

Procurement documents are not analyzed; detailed requirements, terms, and conditions may impose unforeseen obligations.

Submission deadline in 12 days

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must address viral infections, ARDS, or sepsis resulting from infections.
  • Pathogen-targeted therapeutics (Lot 1) or host-targeted therapeutics (Lot 2).
  • Excludes small molecules, monoclonal antibodies; includes direct/indirect antivirals, immune modulators.

Award Criteria

Lot 1

Quality criterion with weight 80% (per-exa). — 80%Price criterion with weight 20% (per-exa). — 20%

Lot 2

Quality criterion with weight 80% (per-exa). — 80%Price criterion with weight 20% (per-exa). — 20%

Buyer

Location

Brussels, BEL

Identifier

HADEA

Activity

General public services

Lots (2)

LOT-0001

Highly Innovative Therapeutics

Lot 1 targets pathogen-targeted scalable therapeutics, innovative combination therapies, and therapeutics designed for alternative routes to IV administration.

ServicesFrameworkEU fundedElectronic submission

EUR 252M

Estimated value

Duration

108 MONTH

Category

Research

Award Criteria

Best price-quality ratio

Deadline

Deadline Sep 02, 2026

LOT-0002

Advanced Therapeutics

Lot 2 targets host-targeted scalable therapeutics, innovative combination therapies, and therapeutics designed for alternative routes to IV administration.

ServicesFrameworkEU fundedElectronic submission

EUR 252M

Estimated value

Duration

69 MONTH

Category

Research

Award Criteria

Best price-quality ratio

Deadline

Deadline Sep 02, 2026

Procurement Details

Publication date
01 Jul 2026
Languages
English, Bulgarian

Reference metadata

Legal basis
32024R2509

Reference IDs

Tender ID
456593-2026

Documents (2)

Procurement document 1Submission portal 1

Similar tenders

Spain – Research and experimental development services – Pre-commercial Procurement of an innovative Systemic Sustainability Transition Solution for Health Care Organisations (suHCO)

Oct 9

Germany – Research and development services and related consultancy services – Forschungsprojekt - DZSF - Fledermausschutz bei Tunnelsanierungen

Aug 21

France – Research and experimental development services – Chambre d’essais pour des tests en Compatibilité Electro-Magnétique (CEM) d’équipements fonctionnant à l’hydrogène

Aug 25

Belgium – Research and experimental development services – Long-term API stockpiling and rapid finished dose form manufacture

Sep 21

Norway – Research and development services and related consultancy services – Preventive conversations as a means of the police ́s preventive work.

Sep 8

Germany – Research and experimental development services – Toolkit für aktives Verteilnetzmanagement

Aug 31